Literature DB >> 9669389

Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.

J Barbet1, P Peltier, S Bardet, J P Vuillez, I Bachelot, S Denet, P Olivier, F Leccia, B Corcuff, D Huglo, C Proye, E Rouvier, P Meyer, J F Chatal.   

Abstract

UNLABELLED: Pretargeting labeled bivalent hapten with bispecific antibodies has proven feasible in the clinic, and our earlier results have suggested the technique may be very sensitive for detecting small recurrences and metastases. Medullary thyroid carcinoma (MTC) is an example where this technique may be the most useful since local recurrences and isolated metastases are removed surgically when detected, and thyrocalcitonin provides a specific and sensitive tumor marker. In our current study, we evaluated pretargeted immunoscintigraphy in a larger number of MTC patients.
METHODS: Anti-carcinoembryonic antigen (CEA) x anti-diethylenetriaminepentaacetic acid (DTPA) indium bispecific antibody and 111In-labeled bivalent DTPA hapten were administered sequentially (4-5 days apart) to 44 patients with elevated circulating calcitonin after resection of primary MTC. Immunoscintigraphy was performed 2, 5 and 24 hr after hapten injection and, when necessary, at longer time intervals. When available, a handheld gamma probe was used during surgery.
RESULTS: Fifteen patients had known tumor sites before immunoscintigraphy. Tumors were imaged in 12 (80%) of these patients, including 3 with liver metastases. Five unknown tumor sites were detected. For the 29 patients with occult disease, immunoscintigraphy detected high-activity uptake sites in 21 patients (72%), including 5 in the liver. Twelve were confirmed by surgery, 1 by guided morphologic imaging and 1 by venous catheterization. There were 2 false-positive patients. The other 5 patients have not yet been confirmed. All detected liver metastases were high-activity uptake areas. Radioimmunoguided surgery was used in 14 patients. It was considered helpful by the surgeon in 12 patients, including 4 patients where it determined the resection of small, not palpable nor visible, tumor-involved lymph nodes. Surgical resection resulted in a significant decrease (8 patients) or normalization (1 patient) of circulating calcitonin and CEA.
CONCLUSION: This technique affords high sensitivity and specificity for detecting small tumor lesions including liver metastases. Its use for immunoscintigraphy and guided surgery should improve the therapeutic management of recurrent MTC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669389

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.

Authors:  Kelly Davis Orcutt; Khaled A Nasr; David G Whitehead; John V Frangioni; K Dane Wittrup
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

2.  Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.

Authors:  Jiang He; Yi Wang; Shuping Dou; Xinrong Liu; Surong Zhang; Guozheng Liu; Donald Hnatowich
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

3.  Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Authors:  Caroline Rousseau; David M Goldenberg; Mathilde Colombié; Jean-Charles Sébille; Philippe Meingan; Ludovic Ferrer; Pierre Baumgartner; Evelyne Cerato; Damien Masson; Mario Campone; Aurore Rauscher; Vincent Fleury; Catherine Labbe; Alain Faivre Chauvet; Jean-Sebastien Fresnel; Claire Toquet; Jacques Barbet; Robert M Sharkey; Loic Campion; Françoise Kraeber-Bodéré
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

4.  Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.

Authors:  Kelly Davis Orcutt; Adrian L Slusarczyk; Maryelise Cieslewicz; Benjamin Ruiz-Yi; Kumar R Bhushan; John V Frangioni; K Dane Wittrup
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

Review 5.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

Review 6.  Molecular imaging in thyroid cancer.

Authors:  T F Heston; R L Wahl
Journal:  Cancer Imaging       Date:  2010-01-20       Impact factor: 3.909

7.  Computationally Designed Bispecific Antibodies using Negative State Repertoires.

Authors:  Andrew Leaver-Fay; Karen J Froning; Shane Atwell; Hector Aldaz; Anna Pustilnik; Frances Lu; Flora Huang; Richard Yuan; Saleema Hassanali; Aaron K Chamberlain; Jonathan R Fitchett; Stephen J Demarest; Brian Kuhlman
Journal:  Structure       Date:  2016-03-17       Impact factor: 5.006

8.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.

Authors:  David M Goldenberg; Jean-Francois Chatal; Jacques Barbet; Otto Boerman; Robert M Sharkey
Journal:  Update Cancer Ther       Date:  2007-03

9.  Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.

Authors:  Vilma I J Jallinoja; Jacob L Houghton
Journal:  J Nucl Med       Date:  2021-05-20       Impact factor: 10.057

10.  Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.

Authors:  Caroline Bodet-Milin; Alain Faivre-Chauvet; Thomas Carlier; Catherine Ansquer; Aurore Rauscher; Eric Frampas; Frederique Toulgoat; Damien Masson; Mickael Bourgeois; Evelyne Cerato; Vincent Rohmer; Olivier Couturier; Delphine Drui; David M Goldenberg; Robert M Sharkey; Jacques Barbet; Francoise Kraeber-Bodere
Journal:  J Nucl Med       Date:  2021-02-05       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.